[go: up one dir, main page]

TWI237637B - 5-trityloxymethyl-oxazolidinones and process for the preparation thereof - Google Patents

5-trityloxymethyl-oxazolidinones and process for the preparation thereof Download PDF

Info

Publication number
TWI237637B
TWI237637B TW090122961A TW90122961A TWI237637B TW I237637 B TWI237637 B TW I237637B TW 090122961 A TW090122961 A TW 090122961A TW 90122961 A TW90122961 A TW 90122961A TW I237637 B TWI237637 B TW I237637B
Authority
TW
Taiwan
Prior art keywords
scope
patent application
item
organic solvent
trityl
Prior art date
Application number
TW090122961A
Other languages
Chinese (zh)
Inventor
Rawle I Hollwgsworth
Guijuin Wang
Original Assignee
Univ Michigan State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan State filed Critical Univ Michigan State
Application granted granted Critical
Publication of TWI237637B publication Critical patent/TWI237637B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for preparing protected, preferably chiral, 5-trityloxymethyl-oxazolidinone in one step directly from optically active 3-hydroxy-4-trityloxy butyramide is described. Oxazolidinones are an important class of molecules in the pharmaceutical industry especially in the areas of antimicrobials and behavioral disorders.

Description

1237637 A7 五、發明説明(01 名稱:5_二苯甲氧甲基4錢_及其製備方法 摘要: —本發明描述-種於單—步財直接自旋光性3遍基冬 二笨甲氧基丁醯胺製備經保護、較佳為對掌性之S三苯甲 虱甲基气吐㈣的方法。σ号口坐咬嗣係為醫藥工業中的一種 重要分子,尤其是在抗微生物劑及行為障礙之領 詳細說明: < ΜΜ相關申諸者朱1 無 展之陵沭 -—0^-- (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 無 發明背景 ⑴發明領坺 本發明有關-種自3-絲·4·三苯^氧基丁醯胺製得5-二苯甲氧甲基噚唑啶酮之單階路徑。本發明尤其有關5_三 苯甲氧甲基谔唑啶酮之對掌性形式的製備。(2) iKMMMAJL 具有光學純度之哼唑啶酮可藉著使用試劑諸如光氣、 氯甲酸乙酯及羰基咪唑使連位胺基醇進行羰基化而製得。 具有光學純度之5·三苯甲氧甲基哼唑啶酮之製備一般需要 製備對應之具有光學純度的5-經甲基哼吐啶酮,之後進行 三苯甲基化步驟,以製得5-三苯甲氧甲基σ号唑啶酮。 °亏峻哫酮類在藥物發展上顯然係極重要的一類化合 物’尤其是抗微生物劑領域中(〇4]^11^,〇.了.等人,〇1'1^59 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 訂 4. 1237637 A7 B7 五、發明説明(02 ) (請先閲讀背面之注意事項再填寫本頁) 7-16 (2000))及行為障礙(Brenner,R等人,cnn 丁以以^如22 4 411-419 (20_。尤其具有對抗部分最具抗藥性之人類病 原的活性,包括抗萬古黴素腸球菌、抗甲氧苯青黴素金黃 色葡萄球菌、抗頭孢菌素肺炎鏈球菌及數種顯示抗青徽素 性貝之有機物(Diekema’ D· J.等人,j)rugs 59 7-16 (2000))。 林若利(LineZ〇id)(4)係最近建議用以治療抗生素抗藥性菌株 之感染的藥物,尤其是抗萬古黴素者。1237637 A7 V. Description of the invention (01 Name: 5_Dibenzomethylmethyl 4-money_ and its preparation method Abstract:-Description of the invention-Kind of single-Bucai direct spin optical properties of 3 times Jidong Dibenjia Method for the preparation of protected but preferably palmitic S-tribenzyl methacetate by oxybutyramine. The sigma-stomach σ is an important molecule in the pharmaceutical industry, especially in antimicrobials Agents and Behavioral Disorders Details: < MM Related Applicant Zhu 1 Tomb of Wuzhan --- 0 ^-(Please read the precautions on the back before filling out this page) Staff Consumer Cooperatives, Central Standards Bureau, Ministry of Economic Affairs Printed without background of invention (Invention collar) The present invention relates to a single-stage path for preparing 5-dibenzyloxymethyloxazolidinone from 3-sil · 4 · triphenyl ^ butoxymidine. This invention It is particularly relevant to the preparation of the palmitate form of 5-tribenzyloxymethyloxazolidinone. (2) iKMMMAJL The oxazolidinone with optical purity can be obtained by using reagents such as phosgene, ethyl chloroformate and carbonylimidazole It is prepared by carbonylating a vicinal amine alcohol. Preparation of 5. · tribenzyloxymethyl oxazolidone with optical purity In general, it is necessary to prepare the corresponding 5-transmethyl humidone with optical purity, and then perform a tritylation step to obtain 5-tribenzyloxymethyl sigmazodone. ° 哫 峻 哫Ketones are obviously a very important class of compounds in drug development, especially in the field of antimicrobial agents (〇4] ^ 11 ^ , 〇. 了. Et al., 〇1'1 ^ 59 This paper standard applies to Chinese national standards ( CNS) A4 specification (210X297 mm) Order 4. 1237637 A7 B7 V. Description of the invention (02) (Please read the notes on the back before filling this page) 7-16 (2000)) and behavioral disorders (Brenner, R, etc. Human, cnn Ding Yi ^ such as 22 4 411-419 (20_. Especially has activity against some of the most resistant human pathogens, including vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, anti-cephalosporin Streptococcus pneumoniae and several organisms that show resistance to cyanogenin (Diekema 'D. J. et al., J) rugs 59 7-16 (2000)). LineZoid (4) is a recent recommendation Drugs used to treat infections with antibiotic-resistant strains, especially those resistant to vancomycin.

旋光性3,4-二羥基丁酸及其r-内酯係為對掌性之重要 來源。其可於工業量下藉著氧化降解而得自醣類諸如澱粉、 乳糖、麥芽糖糊精、纖維素及阿拉伯糖(Hollingsworth,R.I. Biotechnology Annual Review 2 281-291 (1996); 經濟部中央標準局員工消費合作社印製Optically active 3,4-dihydroxybutyric acid and its r-lactone are important sources of palmity. It can be obtained from sugars such as starch, lactose, maltodextrin, cellulose and arabinose by oxidative degradation in industrial quantities (Hollingsworth, RI Biotechnology Annual Review 2 281-291 (1996); employees of the Central Standards Bureau of the Ministry of Economic Affairs Printed by Consumer Cooperatives

Hollingsworth,R.I.,J. Org. Chem. 64 7633-7634 (1999))。亦 參照 Hollingsworth 之美國專利第 5,292,939 號、第 5,080,107 號、第5,319,110號及第5,374,773號。對掌性胺基丙烷二 醇可藉著旋光性3,4-二羥基丁酸醯胺之亞異丙基縮醛的霍 夫曼(Hoffman)降解而製得(Wang,G.等人,J· Org. Chem· 64 1036-1038 (1999))。 發明概述 本發明有關一種製備5-三苯甲氧甲基谔唑啶酮之方 法,其包括: 5 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) !237637 Μ 經濟部中央標準局員工消費合作社印製 五、發明説明(〇3 ) (a) 於驗金屬或鹼土金屬氫氧化物及有機溶劑存在下, 知反應奶合物中之3,4-二幾基丁酿胺的4-三苯甲基與驗 金屬或驗土金屬次卣酸鹽攪拌於水中以進行反應,而製得 5 -三苯甲氧甲基4 π坐咬酮; (b) 自有機落劑中之反應混合物分離該5-三苯甲氧甲基 。号唑啶酮;及 (c) 移除忒有機溶劑,以製得該5_三苯甲氧甲基呤唆啶 酉同。 本發明亦有關藉該方法製的之新穎5_三苯甲氧甲基。号 唑啶酮1。該化合物以對掌性為佳。 發明目的 因此,本發明之目的係提出一種可自酿胺之三苯甲基 _產製新穎4 5·三苯甲氧甲基酮的單階方法。此外, 本發明之一目的係提出對掌性產物之製備。此外,本發明 《目的係提出一種較先前技藝簡易且經濟之方法,於高 率及純度下產製該產物。參考以下y、+、 ° >亏以下描逑可更加明瞭此 其他目的。 較佳具體實例描沭 本發明方法所涉及之反應係如以下危 1况乜圖1所示。 Η 一 ΟΗ 〇 2 ΟΟΓ/ΟΗΓ •- νη2Hollingsworth, R.I., J. Org. Chem. 64 7633-7634 (1999)). See also U.S. Patent Nos. 5,292,939, 5,080,107, 5,319,110, and 5,374,773 of Hollingsworth. Palmitic aminopropanediol can be prepared by Hoffman degradation of isopropylidene acetal of optically active 3,4-dihydroxybutyric acid amine (Wang, G. et al., J Org. Chem. 64 1036-1038 (1999)). SUMMARY OF THE INVENTION The present invention relates to a method for preparing 5-tribenzyloxymethyloxazolidone, which includes: 5 paper sizes applicable to Chinese National Standard (CNS) A4 (210 X 297 mm)! 237637 Μ Ministry of Economic Affairs Printed by the Consumer Standards Cooperative of the Central Bureau of Standards V. Description of the Invention (〇3) (a) In the presence of metal or alkaline earth metal hydroxides and organic solvents, it is known that 3,4-dichlorobutanol in the reaction milk compound 4-tritylamine of amine and metal or earth metal hyporhenate are stirred in water for reaction to obtain 5-trityloxymethyl 4 π sitting bite ketone; (b) from organic solvents The reaction mixture in was isolated from the 5-trityloxymethyl group. Nozolidinone; and (c) removing the hydrazone organic solvent to obtain the 5-tribenzylmethoxine pyridine pyridine. The invention also relates to a novel 5-trityloxymethyl group made by this method. No. azolidinone 1. The compound is preferably palmar. OBJECTS OF THE INVENTION Therefore, the object of the present invention is to propose a single-stage method for producing novel 4 5 · trityloxymethyl ketones from a trityl group that can be brewed from amines. In addition, one object of the present invention is to propose the preparation of palm products. In addition, the purpose of the present invention is to propose a simpler and more economical method than the previous technique to produce the product at a high rate and purity. Refer to the following y, +, ° > descriptions below to make this other purpose more clear. The description of the preferred embodiment is as follows: The reaction involved in the method of the present invention is shown in Figure 1 below. Η 一 ΟΗ 〇 2 ΟΟΓ / ΟΗΓ •-νη2

Scheme 6 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐 ------噥------1T-----d (請先閱讀背面之注意事項再填寫本頁)Scheme 6 This paper size applies to China National Standard (CNS) A4 specifications (210X297 mm ------ 哝 ------ 1T ----- d (Please read the precautions on the back before filling this page )

I 經濟部中央標準局員工消費合作社印製 二個步驟係於以下條件下進行三苯甲基嶋之重上yI Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs

本紙張尺度適 (210x297公釐) 1237637 五、發明説明(05 ) 該胺驗以吼读為佳,唯可使用其他胺類諸如三乙胺,以血 該反應中所產製之HCI或其他酸進行反應。該有機溶劑以、 二甲基甲醯胺與四氫吱喃之混合物為佳,不含水。該溶叫 較佳㈣真f移除,之後使用己垸洗條乙醚,以移除過i 4二麥T基ϋ。該溫度係介於約5。& 4Q<t之間,而壓力 係為 大氣壓。該反應係於24至48小時内完成。隨後使用此三 麥甲基酸以形成該°号口坐途g同。 因此,本發明提出一種經三苯甲基保護、具 度之5-經甲基+坐咬酉同諸如⑻_5-三苯甲氧基甲基4㈣ 酉同⑴’其係在簡易之高產率方法中’使用對掌性3,心二經 基I祕《4-0-三苯甲基_為起始物質,而自旋光性弘 嫂基-r-丁内酯製得。 ^為^水進行水解之異氰酸㈣為霍夫曼(祕 =中(中間物質’基本上連位經基可作為導致環化之親 形成酮系統。於本發明中,避免使用光氣、 =:?:分個別羰基化反應。此係說 基丁酸_(狀4:=酸仙一二- 包括开% 序基本上僅包括兩個步驟,其中僅有一個 己# ^ 1。第—步驟係、自二經基丁 S!胺2---種 氨水溶液處理3-Λ二二基此驢胺係於室溫下使用 t巷-7 -丁内酯而於定量 I 1T (請先閲讀背面之注意事項再填寫本f) 1237637 A7 五、發明説明(06 中間體異氰酸酿⑶係經保護以隔離水,使得相鄰之幾基參 與’同時保護最終產物以防止驗水解。使用2相溶劑系統_ -此情況下為四氫吱喃/水—之霍夫曼重排直接產生細保確 之幾甲基十坐咬丄,單離產率>9〇卩分比,而光學純度>9又9 百分比。此情況表示於基本上4步驟中自殿粉、麥芽糖、 «或類似4_經鍵結醣來源合成重要、具光學純度、㈣ 狀5-(禮甲基峻相的極重要經濟性。該三苯甲基 可選擇性地移除,使得該H甲基官能性轉變成各式久樣之 取代基。該環氮亦可藉著置換氫而經垸基化或驢化^兩 特徵使其可輕易得到極大·之可能藥物候選物。 實施例 訂 /下係為製備經保護5_三苯甲氧基甲基_嘮唑啶酮之步 濟 部 中 央 準 員 工 消 f 合 作 社 印 3-羥基三苯甲氧基丁醯胺⑺之製備Μ”克莫 耳)(S)-3,4-二經基-丁酸胺溶解於5〇毫升四氫咬喃及% = =二甲基甲醯胺中,添加1G毫升_基,之後為·克(〇二 莫耳)三苯甲基氯於燒瓶中。使用充填有氯化鈣之乾燥管以 排除濕氣。該反應混合物於室溫下攪掉36小時。此周期乂 後,過濾以移除固體。該液體於減壓下濃縮,以移除大= 分溶劑。該溶液倒入冰水中,攪拌半小時,自經三笨# 保護之醯胺移除水層。所得之半結晶狀液體產物於=基 乾燥。使用己烷濕磨以洗除過量之三苯甲基氯。產量^下 33.0克(91百分比)。物理數據:熔點59|6〇〇它(得=== 二氯甲烷:己烷:丙酮= 6:3:〇·5)〔 α〕'Mb。(二^劑 本紙張尺關家鮮(c叫公I y 1237637 A7 B7 五、發明説明(08 ) (Mosher’s acid))衍生物之GC分析,產物之光學純度>99.9 e.i 熟習此技藝者可依習用方式將該5-三苯甲氧基甲基-呤唑啶 酮脫保護(例如氫解或HBr處理),而用以製備重要之5-乙 醯胺甲基呤唑啶酮(如各個專利所述,例如Pearlman等人 之美國專利第5,837,870號)。該羥基可藉任何已知方法轉 化成含氮之官能基。此等方法係包括甲磺醯化或甲苯磺醯 化,之後使用氨、疊氮化物、苄基胺及其他氮親核劑置換, 如以下流程圖2所示。 人 .MesylcWoride 9 」 十 ^ R Pyridke- 1 R 1 ίί" or-H2The size of this paper is suitable (210x297 mm) 1237637 V. Description of the invention (05) The amine test is better to read out. Only other amines such as triethylamine can be used to produce HCI or other acids produced in this reaction. Perform the reaction. The organic solvent is preferably a mixture of dimethylformamide and tetrahydrofuran, and does not contain water. The solvent is preferably removed, and then washed with diethyl ether to remove i 4 dimethyl T-based hydrazone. This temperature is between about 5. & 4Q < t, and the pressure is atmospheric. The reaction was completed in 24 to 48 hours. This triglycinic acid is subsequently used to form the mouthpiece g. Therefore, the present invention proposes a triphenylmethyl-protected, 5-methyl group + seat bite with a degree such as ⑻_5-tritylmethoxymethyl 4 酉 酉 with ⑴ ', which is in a simple and high yield method 'Using palmarity 3, the cardinal dimer radical I, "4-0-trityl-" as the starting material, and spin optically sulfonyl-r-butyrolactone. ^ Isocyanate hydrolyzed by water is Huffman (secret = medium (intermediate substance 'basically connected via a radical can be used as a cyclization to form a ketone system. In the present invention, the use of phosgene, =:?: Divided into individual carbonylation reactions. This is said that butyric acid _ (like 4: = acid succinic acid-including open %% sequence basically consists of only two steps, of which only one has ## 1. 第 — Steps are based on the treatment of 2-butyridine S! Amine 2 --- ammonia solution in aqueous 3-Λdidiyl. This donkey amine is used at room temperature to quantify I 1T (please first Read the notes on the back and fill in this f) 1237637 A7 V. Invention description (06 Intermediate isocyanate is protected to isolate water, so that adjacent groups participate in 'while protecting the final product to prevent hydrolysis. Use 2-Phase Solvent System _-In this case, Tetrahydrocondensate / water-the Huffman rearrangement directly produces a few fidelity methyl succinates, with an isolated yield of> 90%, and Optical purity> 9 and 9 percentages. This condition indicates that in 4 basic steps, the synthesis from the powder, maltose, «or similar 4_ bond sugar source is important, bright Purity, 5--like 5- (methyl ether phase is very important economical. The trityl group can be selectively removed, so that the H methyl functionality is transformed into a variety of substituents. The ring nitrogen It can also be replaced by hydrogen to be fluorinated or donated. The two characteristics make it easy to obtain a possible drug candidate with great potential. The example / underline is to prepare a protected 5-triphenylmethoxymethyl group. Oxidazolidone Preparation by the Central Associate of the Ministry of Economic Affairs, Cooperative Society, Preparation of 3-Hydroxytriphenoxybutyridamine, ”" Mkol ", (S) -3,4-Dimethyl-butyric acid amine Dissolved in 50 ml of tetrahydrofuran and% == dimethylformamide, add 1G ml_ group, and then · g (0 mol) of trityl chloride in the flask. Use filled with chlorine Dry the tube of calcium to remove moisture. The reaction mixture was stirred off at room temperature for 36 hours. After this period of time, it was filtered to remove solids. The liquid was concentrated under reduced pressure to remove large solvents. The solution was poured into ice water and stirred for half an hour, and the aqueous layer was removed from the stilbamine protected by Sanben #. The obtained semi-crystalline liquid product was dried on a base. Wet mill to wash away excess trityl chloride. Yield: 33.0 g (91%). Physical data: melting point 59 | 600 (it is === dichloromethane: hexane: acetone = 6: 3: 〇 · 5) [α] 'Mb. (Two copies of this paper ruler Guan Jiaxian (c is called public y 1237637 A7 B7 V. Description of the invention (08) (Mosher's acid)) GC analysis of the derivative, the product Optical purity> 99.9 ei Those who are familiar with this technique can deprotect the 5-triphenoxymethyl-pyrazolidone (such as hydrogenolysis or HBr treatment) according to customary methods, and use it to prepare important 5- Acetaminophenmethylpyrazolidone (as described in various patents, such as US Patent No. 5,837,870 to Pearlman et al.). The hydroxyl group can be converted into a nitrogen-containing functional group by any known method. These methods include mesylation or tosylation, followed by substitution with ammonia, azide, benzylamine, and other nitrogen nucleophiles, as shown in Scheme 2 below. People .MesylcWoride 9 '' Ten ^ R Pyridke- 1 R 1 ίί " or-H2

〇A〇A

R I------I-丨~#-I (請先閲讀背面之注意事項再填寫本頁)R I ------ I- 丨 ~ # -I (Please read the notes on the back before filling this page)

MsOMsO

〇 NT HO、〇 NT HO,

Ο N ‘ TrOΟ N ‘TrO

0)N3. (b) H2 / catalyst (c) Ac200) N3. (B) H2 / catalyst (c) Ac20

00A 〇 NH00A 〇 NH

* · *聿 RX plu^ catalyst (X = halogen) H0 〇H* · * 聿 RX plu ^ catalyst (X = halogen) H0 〇H

、1T, 1T

又 〇 N AcHN〇 N AcHN

ΟΕΓ _· 經濟部智慧財產局員工消費合作社印製ΟΕΓ _ · Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs

OK HO NH2OK HO NH2

叉 〇 NH HOFork 〇 NH HO

HO NH2 HOHO NH2 HO

Scheme 2Scheme 2

TrO. 前文描述僅用以說明本發明,而本發明僅受限於以下 申請專利範圍。 11 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐)TrO. The foregoing description is only used to illustrate the present invention, and the present invention is limited only by the scope of the following patent applications. 11 This paper size applies to China National Standard (CNS) Α4 specification (210X297 mm)

Claims (1)

走237637 第090122961號 94年〇5月18日 替換修正本 (01) 申請專利範圍 '一種製備5-三苯甲氧甲基-谔唑啶酮之方法,其包括· (a) 於驗金屬或鹼土金屬氫氧化物及有機溶劑存在 下,將反應混合物中之3,4-二羥基丁醯胺的‘三苯甲 基醚與鹼金屬或鹼土金屬次_酸鹽攪拌於水中以進行 反應,而製得孓三苯甲氧甲基呤唑啶酮; (b) 自有機/谷劑中之反應混合物分離該三苯甲氧甲 基谔峻淀酮;及 (c) 移除該有機溶劑,以製得該三苯甲氧甲基嘮唑 啶酮。 - 2 3 5 6 如申請專利範圍第!項之方法,其中該驗金屬或驗土 金屬氫氧化物係為氫氧化鈉。 如申請專利範圍第!或2項之方法,其中該有機溶劑 係於步驟(b)中藉分層而自水分離。 ^申請專利範圍第1項之方法,其中該有機溶劑係藉 蒸發移除。 如申請專利範圍第!項之方法,其中在步驟⑷之後, =5-三苯甲基_甲基#錢_藉著於乾燥劑存在下溶 ;一虱甲烷中,之後移除該二氯甲烷而純化。 二^申請專利範圍第!項之方法,其中步驟⑷中之3,心 舍=基丁醯胺之4-三苯甲基醚係藉著過量之三苯甲基 3’4_二#1基丁 _於有機中於胺鹼存在下進行反 〜產生4-三苯甲基醚,其以水洗除 移除過量之三苯甲魏。 先除而^谷劑卒取 12 (02) (02) 如申請專利範圍第1項之方法,其中今 甲基十K係旋光純的。 笨甲氧 如申請專利範圍第!項之方法,其中謗有機溶劑係為 機溶劑係為 南酸鹽係為 !237637 四氫咬喃 9、 κ 如申請專利範圍第1項之方法,其中該有 —口惡境。 10、 如申請專利範圍第1項之方法,其中次 次氯酸鹽。 11、 如申請專利範圍第1項之方法,其中該次 為次溴酸鹽。 12、 如申請專利範圍第1項之方法,其中該有 為水不溶性醇。 二冬甲氧甲基-σ号吐淀嗣。 鹵酸鹽係 機溶劑係 13237637 No. 090122961 No. 090122961, May 18, 1994 Replacement of the revised version (01) Application for patent scope 'A method for preparing 5-tribenzyloxymethyl-oxazolidinone, which includes: (a) testing metal or In the presence of an alkaline earth metal hydroxide and an organic solvent, the 'trityl ether of 3,4-dihydroxybutanamine in the reaction mixture and an alkali metal or alkaline earth metal hypochlorite are stirred in water for reaction, and (B) isolating trityloxymethylpyrazolone; (b) separating the trityloxymethylpyridoxone from the organic / cereal reaction mixture; and (c) removing the organic solvent to This tribenzomethoxymethyloxazolidone was obtained. -2 3 5 6 If the scope of patent application is the highest! The method of clause, wherein the metal or soil metal hydroxide is sodium hydroxide. Such as the scope of patent application! Or the method of item 2, wherein the organic solvent is separated from water in step (b) by layer separation. ^ The method of claim 1 in which the organic solvent is removed by evaporation. Such as the scope of patent application! The method according to the item, wherein after step =, = 5-trityl_methyl ## _ is purified by dissolving in the presence of a desiccant; methane, and then removing the dichloromethane. Second ^ the scope of patent application! Item method, wherein step 3 in step IX = 4-trityl ether of butylamidine is obtained by using an excess of trityl 3'4_di # 1 butylbutyl_ in organic The reaction is carried out in the presence of a base to produce 4-trityl ether, which is washed away with water to remove excess tritylwei. Divide first and take gluten extract 12 (02) (02) The method according to item 1 of the patent application range, in which methyl 10K is optically pure. Stupid Methoxylate The method of item 1, in which the organic solvent is organic solvent, the sodium salt is! 237637 Tetrahydrooctane 9, and κ The method of item 1 in the scope of patent application, which has-bad mouth conditions. 10. For the method in the first scope of patent application, in which hypochlorite is used. 11. The method of claim 1 in the scope of patent application, wherein this time is hypobromite. 12. The method according to item 1 of the scope of patent application, wherein this is a water-insoluble alcohol. Dioxomethoxymethyl-σ No. Tudou. Halate based organic solvents 13
TW090122961A 2000-09-19 2001-09-19 5-trityloxymethyl-oxazolidinones and process for the preparation thereof TWI237637B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/665,508 US6288239B1 (en) 2000-09-19 2000-09-19 5-trityloxymethyl-oxazolidinones and process for the preparation thereof

Publications (1)

Publication Number Publication Date
TWI237637B true TWI237637B (en) 2005-08-11

Family

ID=24670388

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090122961A TWI237637B (en) 2000-09-19 2001-09-19 5-trityloxymethyl-oxazolidinones and process for the preparation thereof

Country Status (10)

Country Link
US (1) US6288239B1 (en)
EP (1) EP1324989B1 (en)
JP (1) JP3974035B2 (en)
KR (1) KR100525882B1 (en)
AT (1) ATE329910T1 (en)
AU (2) AU7593701A (en)
CA (1) CA2418200C (en)
DE (1) DE60120729D1 (en)
TW (1) TWI237637B (en)
WO (1) WO2002024670A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773218B2 (en) * 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
EP1560584B1 (en) * 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
AU2002367959A1 (en) * 2001-10-18 2003-12-31 Michigan State University Process for the preparation of oxazolidinones and method of use thereof
ES2518316T3 (en) * 2002-12-06 2014-11-05 Debiopharm International Sa Heterocyclic compounds, their manufacturing methods and their use in therapy
ATE409485T1 (en) * 2003-03-17 2008-10-15 Affinium Pharm Inc PHARMACEUTICAL COMPOSITIONS CONTAINING FAB I INHIBITORS AND OTHER ANTIBIOTICS
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en) * 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
KR200453944Y1 (en) * 2011-03-08 2011-06-03 조명호 Food delivery container
SMT201900411T1 (en) 2012-06-19 2019-09-09 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
SMT202000719T1 (en) 2016-02-26 2021-03-15 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
HUE062061T2 (en) 2019-02-14 2023-09-28 Debiopharm Int Sa Afabicin formulation, method for making the same
UA129222C2 (en) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Afabicin for use for treating bacterial infections involving biofilm

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122601A (en) * 1990-12-07 1992-06-16 Hawaiian Sugar Planters'association Synthesis of 2,3,3',4,4'-penta-o-methylsucrose
CA2049536C (en) 1991-05-13 1999-07-06 Rawle I. Hollingsworth Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof
CZ298060B6 (en) 1996-04-11 2007-06-06 Pharmacia & Upjohn Company Process for preparing oxazolidinones
US5808107A (en) 1997-10-31 1998-09-15 Board Of Trustees Operating Michigan State University Process for the preparation of hydroxy substituted gamma butyrolactones
IT1301977B1 (en) * 1998-07-31 2000-07-20 Sigma Tau Ind Farmaceuti PROCEDURE FOR THE PREPARATION OF R - (-) - CARNITINA

Also Published As

Publication number Publication date
ATE329910T1 (en) 2006-07-15
JP3974035B2 (en) 2007-09-12
EP1324989B1 (en) 2006-06-14
AU7593701A (en) 2002-04-02
CA2418200A1 (en) 2002-03-28
DE60120729D1 (en) 2006-07-27
CA2418200C (en) 2006-07-04
JP2004523473A (en) 2004-08-05
WO2002024670A1 (en) 2002-03-28
EP1324989A1 (en) 2003-07-09
EP1324989A4 (en) 2005-07-20
KR100525882B1 (en) 2005-11-02
KR20030025301A (en) 2003-03-28
AU2001275937B2 (en) 2005-08-11
US6288239B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
TWI237637B (en) 5-trityloxymethyl-oxazolidinones and process for the preparation thereof
JP4278511B2 (en) N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds
TW204336B (en)
HU225810B1 (en) Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use
JP2004517090A5 (en)
US20220135614A1 (en) Synthesis of bicycle toxin conjugates, and intermediates thereof
TW200913998A (en) Heterocycle-aryl compounds for inflammation and immune-related uses
Moynihan et al. Impurity occurrence and removal in crystalline products from process reactions
JP6644685B2 (en) Preparation of pomalidomide and improved method for its purification
EP1807421B1 (en) 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof
JP2011529451A5 (en)
TW425392B (en) Oxazolidinonecarboxylic acid derivatives for use as adhesion receptor antagonists preparation process therefor and pharmaceutical composition comprising the same
CN103764648B (en) Pyrrolidin-3-ylacetic acid derivatives
WO2008003855A2 (en) Use of 2-benzoyl-imidazopyridines in therapeutics
JP2008222630A (en) PRODUCTION METHOD OF R-II TYPE CRYSTAL OF 1-beta-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE
JP2005187357A (en) Method for producing benzothiazolone derivative having selective β2 receptor agonist activity
WO2017025031A1 (en) Diazaoxa heterocyclic spiro-dione piperazine alkaloid derivative having antiviral activity and preparation method thereof
TW201019951A (en) Novel semi-synthetic glycopeptides as antibacterial agents
US10961194B2 (en) Method for purifying ropinirole hydrochloride
TWI230157B (en) Process for the preparation of 5-hydroxymethyl 2-oxazolidinone and novel intermediate
US20250109126A1 (en) Dihydro-oxazol derivative compounds
US20110105763A1 (en) Process for Preparing Valsartan
FR2903108A1 (en) USE OF IMIDAZO [1,2-A] PYRIDINE-2-CARBOXAMIDE DERIVATIVES IN THERAPEUTICS.
CA2371222C (en) Functionalised solid support for alpha-oxoaldehyde synthesis
CS243485B2 (en) Method of benzothienylglycylcephaelosporines production

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees